South Korea · Delayed Price · Currency is KRW S.Biomedics Statistics
Total Valuation
S.Biomedics has a market cap or net worth of KRW 389.51 billion. The enterprise value is 400.03 billion.
| Market Cap | 389.51B |
| Enterprise Value | 400.03B |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
S.Biomedics has 12.39 million shares outstanding. The number of shares has increased by 3.68% in one year.
| Current Share Class | 12.39M |
| Shares Outstanding | 12.39M |
| Shares Change (YoY) | +3.68% |
| Shares Change (QoQ) | +3.18% |
| Owned by Insiders (%) | 21.64% |
| Owned by Institutions (%) | n/a |
| Float | 9.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 23.63 |
| PB Ratio | 23.30 |
| P/TBV Ratio | 50.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 24.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.87, with a Debt / Equity ratio of 0.79.
| Current Ratio | 1.87 |
| Quick Ratio | 1.53 |
| Debt / Equity | 0.79 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.10 |
| Interest Coverage | -6.65 |
Financial Efficiency
Return on equity (ROE) is -41.23% and return on invested capital (ROIC) is -18.22%.
| Return on Equity (ROE) | -41.23% |
| Return on Assets (ROA) | -14.73% |
| Return on Invested Capital (ROIC) | -18.22% |
| Return on Capital Employed (ROCE) | -33.31% |
| Weighted Average Cost of Capital (WACC) | 10.90% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.40 |
| Inventory Turnover | 3.97 |
Taxes
In the past 12 months, S.Biomedics has paid 250.51 million in taxes.
| Income Tax | 250.51M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +40.57% in the last 52 weeks. The beta is 1.22, so S.Biomedics's price volatility has been higher than the market average.
| Beta (5Y) | 1.22 |
| 52-Week Price Change | +40.57% |
| 50-Day Moving Average | 30,711.00 |
| 200-Day Moving Average | 29,357.90 |
| Relative Strength Index (RSI) | 52.42 |
| Average Volume (20 Days) | 86,088 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, S.Biomedics had revenue of KRW 16.48 billion and -8.22 billion in losses. Loss per share was -683.17.
| Revenue | 16.48B |
| Gross Profit | 7.71B |
| Operating Income | -9.64B |
| Pretax Income | -6.77B |
| Net Income | -8.22B |
| EBITDA | -7.39B |
| EBIT | -9.64B |
| Loss Per Share | -683.17 |
Balance Sheet
The company has 11.14 billion in cash and 13.15 billion in debt, with a net cash position of -2.01 billion or -162.58 per share.
| Cash & Cash Equivalents | 11.14B |
| Total Debt | 13.15B |
| Net Cash | -2.01B |
| Net Cash Per Share | -162.58 |
| Equity (Book Value) | 16.71B |
| Book Value Per Share | 662.80 |
| Working Capital | 7.40B |
Cash Flow
In the last 12 months, operating cash flow was -7.26 billion and capital expenditures -4.67 billion, giving a free cash flow of -11.94 billion.
| Operating Cash Flow | -7.26B |
| Capital Expenditures | -4.67B |
| Depreciation & Amortization | 2.26B |
| Net Borrowing | -1.37B |
| Free Cash Flow | -11.94B |
| FCF Per Share | -963.77 |
Margins
Gross margin is 46.75%, with operating and profit margins of -58.51% and -49.87%.
| Gross Margin | 46.75% |
| Operating Margin | -58.51% |
| Pretax Margin | -41.09% |
| Profit Margin | -49.87% |
| EBITDA Margin | -44.80% |
| EBIT Margin | -58.51% |
| FCF Margin | n/a |
Dividends & Yields
S.Biomedics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.68% |
| Shareholder Yield | -3.68% |
| Earnings Yield | -2.11% |
| FCF Yield | -3.06% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
S.Biomedics has an Altman Z-Score of 5.64 and a Piotroski F-Score of 2.
| Altman Z-Score | 5.64 |
| Piotroski F-Score | 2 |